Invariant natural killer T cells (i NKT cells) have a prominent role during infection and other inflammatory processes, and these cells can be activated through their T cell antigen receptors by microbial lipid antigens. However, increasing evidence shows that they are also activated in situations in which foreign lipid antigens would not be present, which suggests a role for lipid self antigen. We found that an abundant endogenous lipid, b-d-glucopyranosylceramide (b-GlcCer), was a potent i NKT cell self antigen in mouse and human and that its activity depended on the composition of the N-acyl chain. Furthermore, b-GlcCer accumulated during infection and in response to Toll-like receptor agonists, contributing to i NKT cell activation. Thus, we propose that recognition of b-GlcCer by the invariant T cell antigen receptor translates innate danger signals into i NKT cell activation.
Invariant natural killer T (iNKT) cells constitute a subset of αβ T cells that recognize lipid antigens presented by the nonpolymorphic CD1d molecule. In contrast to peptide-specific diverse αβ T cell antigen receptor (TCR) major histocompatibility complex (MHC)-restricted T cells, these cells have an invariant TCR α-chain that uses TCR α-chain variable region 14 (V α 14) and α-chain joining region 18 (J α 18) paired with a limited V β chain repertoire in mouse or V α 24 and J α 18 paired with V β 11 in human. How iNKT cells, with an invariant TCR, restricted by a nonpolymorphic antigen-presenting molecule are activated in a wide variety of infectious and non-infectious pathological processes is not well understood 1, 2 .
Much effort has focused on the identification of lipids that are cognate antigens for the iNKT cell TCR. The discovery of the pharmacologic antigen α-galactosylceramide (α-GalCer) 3 , as well as the discovery of glycolipid antigens from the bacteria Borrelia burgdorferi 4 and Sphingomonas 5, 6 , each with a primary α-linked monohexose, suggested the possibility that the major structures recognized by iNKT cells might be α-linked glycolipids. However, recognition of such lipids does not explain the role of iNKT cells during the majority of infections or during inflammation, as primary α-glycosidic linkages have not been shown to occur in most microbes or in mammalian glycolipids. Further, iNKT cells have a major role in situations where foreign lipid antigens would not be present at all, including autoinflammatory conditions, viral infection or stimulation by Toll-like receptors (TLRs) [7] [8] [9] [10] . These observations support a central role for lipid self antigen in the activation of iNKT cells.
The rapid activation of iNKT cells by antigen-presenting cells (APCs) exposed to lipopolysaccharide (LPS) or other TLR agonists is notable [7] [8] [9] [10] and provides a robust and salient model for understanding the response of iNKT cells to innate signals. It is clear that two signals are likely required for the physiological activation of iNKT cells, with the primary signal being provided through the TCR by a CD1dlipid complex and a second signal being provided by APC-derived cytokines, predominantly interleukin 12 (IL-12) 7, 11 . Accumulation of a stimulatory lipid self antigen has been proposed to provide the TCR-mediated signal to iNKT cells after TLR-agonist stimulation 9,10 , but the specific lipid antigen responsible has not been identified.
Phospholipids, including lyso-phosphatidylcholine (lyso-PC), have been proposed to be self antigens for iNKT cells, but their stimulatory activity is weak and has only been shown in a subset of iNKT cells 12, 13 . Isoglobotrihexosylceramide (iGB3) contains a terminal α-linked carbohydrate and can activate mouse iNKT cells through CD1d. Based largely on the observation that Hexb −/− (the Hexb gene product converts iGB4 to iGB3) mice have defective iNKT cell development, this lipid was proposed as a relevant self antigen 14 . However, a subsequent study reported that iGB3-synthase-deficient mice have a normal iNKT cell phenotype 15 , and it has been suggested that the iNKT cell defect in Hexb −/− mice might be caused by altered lysosomal function rather than lower iGB3 concentrations 16 . Further, iGB3 is present in almost undetectable concentrations in mouse lymphoid tissues 17, 18 , and it has also been reported that humans do not express the relevant synthase and are thus unable to synthesize iGB3 (ref. 19) .
In this study, we screened a panel of naturally occurring glycosphingolipids (GSLs) for antigenic activity on iNKT cells. We found that β-d-glucopyranosylceramide (β-GlcCer), which has been reported as being nonantigenic 20 , potently activated iNKT cells in both mouse and human through a cognate TCR interaction. In addition, β-GlcCer, the precursor of most GSLs outside of the central nervous system, accumulated in APCs after stimulation with LPS and accumulated in vivo after bacterial infection. Blocking β-GlcCer synthesis in bone-marrow-derived dendritic cells (BMDCs) resulted in less autoreactivity and iNKT cell activation in response to LPS or whole bacteria, whereas blocking the subsequent step in GSL synthesis, the conversion of β-GlcCer to β-lactosylceramide (β-LacCer), had either no effect or an opposite effect. Our data identify β-GlcCer as a potent, physiologically relevant self antigen for iNKT cells that is upregulated in response to microbial danger signals.
RESULTS

Antigenic activity among a panel of GSLs
To identify self lipids that stimulate iNKT cells, we planned to first isolate the lipids present in CD1d on APCs and then screen those lipids for activity. We have determined the dominant GSLs eluted from CD1d on APCs 21 (summary, Supplementary Table 1 ). β-GlcCer would not have been detected by our previous analysis, as carbohydrate head groups were derivatized after GSL digestion with ceramide glycanase, an enzyme that does not cleave monohexose from a ceramide backbone. For this reason, as we transitioned to the activity determination phase of our iNKT cell antigen-discovery efforts, we included β-GlcCer. We used two assay systems to screen for lipid activity: a single-TCR-specificity iNKT cell hybridoma cultured together with CD1d-trasfected macrophages from the mouse macrophage line RAW and a primary iNKT cell line cultured with primary CD11c + BMDCs. We tested GSLs ( Supplementary Table 1 ) as well as phospholipids, including phosphatidylethanolamine, phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, lyso-PC, lyso-phosphatidylethanolamine, lysophophatidylserine and lyso-phosphatidylinositol. Among the panel of lipids tested, none of the higher-order GSLs or phospholipids was stimulatory. In contrast, the simplest GSL, β-GlcCer, reproducibly activated iNKT cells (Fig. 1a,b and data not shown). In a primary mouse iNKT cell line, we further showed that β-GlcCer elicited the production of both interferon-γ (IFN-γ) and IL-4 ( Fig. 1c,d) , which is a characteristic of TCR-mediated, but not cytokine-mediated, iNKT cell activation 8 . As has been reported for other signals mediated by the iNKT cell TCR, the ability of β-GlcCer to induce iNKT cell IFN-γ production could be enhanced by the addition of IL-12 ( Fig. 1e) , an indirect stimulus for iNKT cells that we proposed as a crucial second signal during infection 7, 11 . We confirmed the chemical composition of bovine milk β-GlcCer by proton nuclear magnetic resonance spectroscopy, two-dimensional correlation spectroscopy and total correlation spectroscopy nuclear magnetic resonance, and we detected no α-anomeric carbohydrate in these analyses (data not shown). From these results, we concluded that an early biosynthetic GSL, β-GlcCer, activates iNKT cells in a CD1d-dependent manner.
b-GlcCer in primary lymphoid tissues
To determine whether β-GlcCer could be detected in tissues that might be sites of iNKT cell activation, we analyzed polar lipids extracted from mouse thymus, spleen, liver and BMDCs by thin layer chromatography (TLC). We observed a monohexosyl ceramide in the thymus, spleen and BMDC extracts ( Fig. 2a) . A detectable but lower amount of monohexosyl ceramide was present in the liver polar lipid extracts. By borate-impregnated TLC analysis, we determined that the monohexosyl ceramide band in the thymus, spleen and BMDC extracts was almost exclusively composed of β-GlcCer and not β-GalCer (Supplementary Fig. 1) . To estimate the β-GlcCer content in these tissues, we used a TLC-based densitometric analysis of the tissue lipid extracts and compared it to a β-GlcCer standard titration.
The β-GlcCer content of mouse thymus, spleen and CD11c + BMDCs was estimated at 4.6 ± 1.1 µg, 3.6 ± 0.8 µg and 3.9 ± 0.1 µg per mg of polar lipids (mean ± s.d.). In order to determine whether the β-GlcCer detected in mammalian lymphoid tissues had stimulatory activity in iNKT cells, we used preparative-scale high-performance liquid chromatography coupled with mass spectrometry to purify β-GlcCer from mouse spleen and thymus crude polar lipid extracts ( Supplementary Fig. 2) . We found the purified β-GlcCer-containing fractions to stimulate an iNKT cell hybridoma in co-culture with CD1dtransfected RAW cells (Fig. 2b) . In the assay shown in Figure 2b , we estimated the β-GlcCer concentrations at 18.0 ± 4.0 µg/ml and 23.0 ± 5.5 µg/ml for the thymus and spleen β-GlcCer fractions, respectively (mean ± s.d.). For the spleen polar lipid extracts, we found that β-LacCer and phospholipid-containing fractions purified by the same method that we used to purify the β-GlcCer fractions were unable to stimulate the iNKT cell hybridoma ( Fig. 2b) . Thus, β-GlcCer is present in mammalian lymphoid tissues, and, when purified from these tissues, activates iNKT cells in a CD1d-dependent manner.
Because β-GlcCer has been reported as being nonantigenic for iNKT cells 20 , we questioned whether the activity of bovine-milk and mammalian β-GlcCer that we observed depends on specific lipid structures attached to the carbohydrate head groups that are present in these purified materials. To address this possibility, we determined the fatty acid compositions of β-GlcCer in bovine milk, mouse spleen and mouse thymus by electrospray ionization mass A r t i c l e s spectrometry (ESI-MS) in the positive-ion mode (Fig. 2c,d and Supplementary Fig. 3 ). We confirmed structural assignments by collision-induced dissociation tandem mass spectrometry as described 22 . In all three samples analyzed, the major ceramide backbone consisted exclusively of sphingenine (d 18:1 ). In mouse thymus, the major N-acyl chains detected were C 24:1 , C 22:0 and C 16:0 . In mouse spleen, the major N-acyl chains detected were C 24:1 , C 24:0 , C 22:0 , C 20:0 and C 16:0 . In bovine milk, the major N-acyl chains detected were C 24:0 , C 23:0 , C 22:0 , C 20:0 and C 16:0 . We present here the structures of two abundant β-GlcCer forms in thymus and spleen ( Fig. 2e) . For all samples, we also detected other β-GlcCer molecular species in smaller quantities, confirming the diversity of N-acyl chains in mammalian GSLs. These results show that the β-GlcCer present in mammalian tissues contains multiple N-acyl chain structures, with C 24:1 being the most abundant of these chains in lymphoid tissues.
b-GlcCer C 24:1 is a potent mouse iNKT cell antigen To functionally test the role of N-acyl chain composition on the activity of β-GlcCer, we studied a panel of synthetic β-GlcCer compounds that all contained sphingenine as the ceramide backbone, with the N-acyl chains varying from 8 to 24 carbons and being either fully saturated or containing one unsaturation ( Supplementary Fig. 4 ). We detected β-GlcCer C 24:1 , C 18:1 , C 18:0 and C 16:0 in primary mouse tissue by ESI-MS, but we did not detect the 12-and 8-carbon N-acyl chain forms of this lipid ( Fig. 2c,d) , and these forms have not, to our knowledge, been reported to occur in mammals. β-GlcCer C 24:1 , C 12:0 and C 18:1 activated an iNKT hybridoma in vitro, whereas β-GlcCer C 18:0 and C 16:0 showed no activity ( Fig. 3a) . Lyso-β-GlcCer (d 18:1 ) and free ceramide backbones corresponding to each synthetic β-GlcCer were not active (data not shown). We then compared the potency of β-GlcCer C 24:1 to the microbial antigen GSL-1 from Sphingomonas 5, 6 and two previously proposed self antigens, iGB3 (ref. 14) and lyso-PC 12 . The iGB3 we used was d 18:1 -C 26:0 , and, although it is not matched to β-GlcCer C 24:1 in N-acyl chain structure, the C 26:0 acyl chain would be expected to impart maximal activity based on data from α-GalCer analogs 23, 24 . As determined by assay with a primary iNKT cell line in co-culture with CD11c + BMDCs, the antigenicity of β-GlcCer C 24:1 was less than that of GSL-1 but was greater than that of iGB3, and, as reported before 25 , we did not detect any activity for lyso-PC in mouse ( Fig. 3b) . Although we did not detect β-GalCer at potential sites of peripheral iNKT cell activation ( Supplementary Fig. 1) , and a β-GalCer-deficient mouse was reported not to have a demonstrable iNKT cell defect 20 , given the structural similarity of β-GalCer to β-GlcCer, we hypothesized that β-GalCer might also activate iNKT cells.
Purified bovine brain β-GalCer, β-GalCer d 18:1 -C 24:1 , and, as shown before 26, 27 , the non-physiological lipid β-GalCer d 18:1 -C 12:0 activated mouse iNKT cells in a CD1d-dependent manner, albeit less potently than each corresponding β-GlcCer ( Supplementary Fig. 5 ).
To examine self antigen activity in vivo, we injected mice intravenously with a subset of the β-GlcCer synthetic panel and iGB3. Two hours after injection with β-GlcCer C 24:1 , two-thirds of liver iNKT cells were IFN-γ positive and greater than 40% were IL-4 positive, which is a substantially higher percentage than that seen in mice injected with iGB3 ( Fig. 3c,d) . In liver mononuclear T cells from CD1d-deficient mice that lack NKT cells, there was no detectable response to β-GlcCer C 24:1 injection. We also observed potent activation of CD11c + dendritic cells and B cells in vivo 24 h after β-GlcCer C 24:1 injection, most likely as a result of transactivation ( Supplementary Fig. 6 ). We concluded from these studies that the activity of β-GlcCer is dependent on the N-acyl chain structure and that the abundant d 18:1 -C 24:1 form of β-GlcCer is a potent antigen for iNKT cells in vivo.
In addition to iNKT cells with an invariant TCR α-chain, there are CD1d-restricted T cells in the diverse αβ TCR compartment called 'diverse NKT cells' . Because there is no method available at present with which to identify primary diverse NKT cells, we screened a panel of ten individual diverse NKT cell hybridomas for activity by coculture with primary mouse BMDCs and the synthetic β-GlcCer panel described above. Two of these ten diverse NKT cell hybridomas, VII68 and XV19 (ref. 28) , showed reactivity to a subset of β-GlcCer compounds ( Supplementary Fig. 7 and data not shown). We concluded from these data that β-GlcCer also activates diverse NKT cells, but that this reactivity may depend on different N-acyl chain structures than do iNKT cells.
b-GlcCer C 24:1 mediates a cognate TCR interaction To confirm that β-GlcCer directly mediates iNKT cell stimulation through CD1d, we tested a synthetic β-GlcCer panel and bovine milk β-GlcCer in an APC-free system with purified, plate-bound CD1d. In this system, bovine milk β-GlcCer, β-GlcCer C 24:1 and β-GlcCer C 12:0 activated a primary iNKT cell line ( Fig. 4a) , showing direct, CD1d-dependent activation of iNKT cells by β-GlcCer. Next, we asked if CD1d tetramers loaded with β-GlcCer C 24:1 could bind iNKT cells directly. Indeed, tetramers loaded with β-GlcCer C 24:1 stained a portion of the iNKT cells from both C57BL/6 and BALB/c mice, as identified by sequential double staining with a CD1d tetramer loaded with PBS-57 (an α-GalCer analog; Fig. 4b ).
The staining seemed to be limited to the portion of the iNKT cells that stained most brightly with the PBS-57-loaded tetramer, suggesting that β-GlcCer C 24:1 -loaded tetramer staining was brightest for the iNKT cell population with the highest affinity TCRs. The TCR V βchain repertoire of mouse iNKT cells is limited, and those cells with the V β -chains V β 2, V β 7, V β 8.1, V β 8.2 and V β 8.3 have been found to have a higher affinity for α-GalCer-loaded CD1d tetramers compared with less frequently used V β -chains (V β 6, V β 9, V β 10 and V β 14) 29 . Consistent with the affinity hierarchy described for α-GalCer-loaded tetramers, β-GlcCer C 24:1 -loaded tetramers identified the most frequently used iNKT cell TCR V β -chains ( Fig. 4c,d) .
Although β-GlcCer tetramer staining was limited to a fraction of mouse iNKT cells (Fig. 4b) , the majority of the iNKT cells produced cytokines after stimulation with β-GlcCer in vivo (Fig. 3) . Further, iNKT cells substantially downregulate their surface TCR expression after activation with a strong antigen but not after indirect activation 30 . Twenty-four hours after intravenous injection of β-GlcCer C 24:1 , iNKT cells were almost undetectable, suggesting TCR-dependent activation of almost all mouse iNKT cells ( Supplementary  Fig. 8) . The difference, then, between iNKT cell activation and tetramer binding is likely because of a higher affinity requirement for tetramer binding relative to activation. We concluded from these tetramer studies that β-GlcCer C 24:1 mediates a cognate interaction between the iNKT cell TCR and CD1d in mouse. b-GlcCer is a self antigen for human iNKT cells Given the high degree of evolutionary conservation seen for both CD1d and iNKT cells 1 , we would expect a physiologically relevant self antigen to activate both mouse and human iNKT cells. We asked whether β-GlcCer was a self antigen in humans by testing the synthetic β-GlcCer panel described above for activity on human iNKT cells. Similar to mouse iNKT cells, β-GlcCer C 24:1 , C 12:0 and, to a lesser degree, C 18:1 , activated three independent human iNKT cell clones 31 when presented by human peripheral blood mononuclear cell (PBMC)-derived APCs, and this activation was efficiently inhibited by a monoclonal antibody against CD1d (Fig. 5a,b ). In this system, iGB3 did not activate iNKT cells. In a primary human iNKT cell line, we compared the antigenic potency of Sphingomonas GSL-1, β-GlcCer C 24:1 , iGB3 and lyso-PC. In humans, β-GlcCer C 24:1 was less potent than GSL-1 but was far more potent than iGB3 or lyso-PC. In fact, in contrast to mouse iNKT cells, we did not detect activity for iGB3 in primary human iNKT cells. Lyso-PC did not stimulate iNKT cells to produce detectable IFN-γ or IL-4, but, as has been reported 12 , we did detect a small amount of granulocyte macrophage colony-stimulating factor ( Fig. 5c and data not shown).
Having shown the activity of β-GlcCer on human iNKT cell clones and a primary human iNKT cell line, we next cultured freshly isolated PBMCs overnight with β-GlcCer without the addition of exogenous APCs and measured iNKT cell intracellular cytokine production. A r t i c l e s β-GlcCer C 24:1 was able to stimulate cytokine production by this assay, and this effect was completely blocked by monoclonal antibody to CD1d (Supplementary Fig. 9a,b) . We also used freshly isolated human PBMCs to assay iNKT cell proliferation in response to various β-GlcCer N-acyl chain variants. β-GlcCer C 24:1 , C 12:0 , and C 18:1 in co-culture led to a marked expansion of iNKT cells over an 8-day period (Supplementary Fig. 9c) .
To confirm the cognate interaction between β-GlcCer-loaded CD1d and the iNKT cell TCR in humans, we made tetramers with β-GlcCerloaded human CD1d. Staining with PBS-57-loaded tetramers allowed for unambiguous identification of iNKT cells, and we confirmed the iNKT cells to be V α 24 + V β 11 + (Fig. 5d) . Double staining of freshly isolated PBMCs with β-GlcCer-loaded CD1d tetramers and PBS-57loaded tetramers showed that a substantial portion of human iNKT cells bind tetramers loaded with β-GlcCer C 24:1 , C 12:0 and C 18:1 (Fig. 5e) .
In complementary experiments, we examined if iNKT cell TCR tetramers 32 could recognize CD1d loaded with β-GlcCer. We again found an interaction dependent on the N-acyl chain, with β-GlcCer C 24:1 and C 12:0 mediating TCR tetramer binding ( Supplementary  Fig. 10a ). β-GlcCer-loaded CD1d tetramer staining was positive but was of variable intensity between subjects ( Supplementary  Fig. 10b) ; for clarity, a subject with a high percentage of β-GlcCer CD1d tetramer-positive iNKT cells is shown in Figure 5 .
As seen in the mouse, β-GlcCer tetramers recognized only a portion of the human iNKT cell population identified by α-GalCer-loaded tetramers. The percentage of cells recognized by β-GlcCer tetramers did not decrease after double staining with α-GalCer tetramers under the staining conditions used, suggesting that tetramer competition was not a factor (data not shown). We hypothesized that, as in the mouse, β-GlcCer tetramers might identify human iNKT cells with high-affinity TCRs. To address this possibility, we used OCH, an α-GalCer analog that, when loaded in human CD1d tetramers, has been reported to bind a population of human iNKT cells with high-affinity TCRs 32 . Double staining with CD1d tetramers loaded with OCH and β-GlcCer C 24:1 identified the same population (Supplementary Fig. 10c ), which suggested that β-GlcCer tetramers identified iNKT cells with high-affinity TCRs. We saw robust iNKT cell activation by β-GlcCer in all human subjects and in all iNKT cell clones tested irrespective of the intensity of β-GlcCer CD1d tetramer staining, which suggested, as in our mouse studies, that tetramer binding may have a more demanding threshold than does iNKT cell activation.
b-GlcCer contributes to iNKT cell self reactivity GSL self lipid antigens have been proposed to contribute to iNKT cell activation in the absence of foreign lipid antigens 33 . Because β-GlcCer is relatively abundant in lymphoid tissues, and because we found that it potently activates iNKT cells from both mice and humans, we postulated that it might contribute to iNKT cell self reactivity. We assessed the contribution of β-GlcCer to iNKT cell autoreactivity by perturbing the pathways involved in the synthesis of this lipid. We present the pathways involved in the synthesis and degradation of β-GlcCer for reference ( Supplementary Fig. 11a) . In a primary mouse iNKT cell line, we found that, as has been shown before 10, 20 , inhibition of GSL synthesis by either N-butyldeoxygalactonojirimycin (NB-DGJ) or D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP) resulted in less iNKT cell autoreactivity (Fig. 6a) .
To assess antigen processing and presentation in BMDCs after treatment with GSL synthesis inhibitors, we used Gal-α-GalCer, an α-GalCer analog that requires lysosomal uptake and processing for antigenicity 34 (Fig. 6b) . NB-DGJ and D-PDMP did not diminish the activation of iNKT cells by Gal-α-GalCer. Because both NB-DGJ and D-PDMP inhibit β-GlcCer synthesis, and, consequently, the synthesis of all higher order ceramides that are based on β-GlcCer, we used small interfering RNA (siRNA) silencing of either glucosylceramide synthase (encoded by Ugcg) or the downstream enzyme that converts β-GlcCer to β-LacCer, lactosylceramide synthase (encoded by B4galt6), in BMDCs to isolate the β-GlcCer-dependent signal (Fig. 6c) . siRNA silencing of Ugcg in BMDCs resulted in less iNKT cell autoreactivity, whereas B4galt6 silencing increased autoreactivity (Fig. 6d) . Silencing through the use of siRNA did not alter the ability of BMDCs to present Gal-α-GalCer ( Fig. 6e) and did not alter CD1d surface concentrations as determined by flow cytometry (Fig. 6f) . Thus, modulation of β-GlcCer concentrations determines iNKT cell self reactivity to BMDCs.
b-GlcCer mediates iNKT cell activation during infection
The iNKT response to LPS-exposed BMDCs requires both a signal through CD1d and APC-derived IL- 12 (refs. 7,9,10) . We hypothesized that β-GlcCer might be a prominent component of an LPS-induced, CD1d-mediated signal and investigated the pathways involved in the synthesis and degradation of β-GlcCer after TLR agonist exposure. Using a published gene-expression data set 35 , we examined the regulation of Ugcg and B4galt6 in mouse BMDCs in response to five TLR agonists. Four of five of the stimuli led to the upregulation of Ugcg, with a peak expression occurring at 2-6 h after exposure to the TLR agonists. All stimuli resulted in a decrease in the expression of B4galt6 mRNA over the first 8 h of exposure to the TLR agonists (Supplementary Fig. 11b) . We saw only minimal changes in the expression of Gba and Glb1, which encode the molecules responsible for the degradation of β-GlcCer and β-LacCer, respectively (data not shown). The LPS concentration used for generation of the dataset above was 100 ng/ml, which is substantially higher than we found to be required to stimulate iNKT cells in co-culture with BMDCs. With 1 ng/ml of LPS, we determined the expression of the genes involved in β-GlcCer metabolism by quantitative PCR and (Fig. 7a) . TLC analysis of polar lipid extracts from CD11c + BMDCs after treatment with LPS showed an increase in β-GlcCer (Fig. 7b) as quantified by densitometry ( Fig. 7c; additional  controls, Supplementary Fig. 12a,b) . Naturally occurring β-GlcCer migrated as a doublet by TLC in the solvent system used, and the potent antigen β-GlcCer C 24:1 migrated in the accumulating upper band (Supplementary Fig. 12c ).
Having shown that β-GlcCer accumulated in BMDCs after TLR agonist stimulation, we next asked whether this lipid contributes to iNKT cell activation. We confirmed that, as has been shown for TLR agonists 9,10 , inhibition of GSL synthesis resulted in a lower response of iNKT cells to LPS-exposed BMDCs (Fig. 7d) . To isolate the β-GlcCer contribution to this GSL-dependent activation, we used siRNA silencing. We found that Ugcg silencing limited the iNKT cell response to LPS-treated BMDCs, whereas B4galt6 silencing enhanced this response (Fig. 7e) . By TLC analysis, we observed lower β-GlcCer concentrations after treatment with NB-DGJ or D-PDMP and after silencing of Ugcg, whereas we saw higher β-GlcCer concentrations after silencing of B4galt6 (Supplementary Fig. 13 ). We did not detect changes in LPS-mediated IL-12 production or BMDC maturation as assessed by flow cytometry after NB-DGJ, D-PDMP or siRNA targeting of Ugcg or B4galt6 compared with controls. D-PDMP did, however, lead to a slight decrease in CD1d surface concentrations on CD11c + BMDCs, potentially contributing to the decreased iNKT cell activation seen after treatment of BMDCs with this inhibitor ( Supplementary Fig. 14) . Alteration in some lipid synthesis pathways has been shown to alter endosomal or lysosomal function and subsequently diminish iNKT cell activation 16 . For that reason, we used confocal fluorescence microscopy to assess the endosomal and lysosomal systems in CD11c + BMDCs after treatment with β-GlcCer synthesis inhibitor or siRNA. We saw no morphological abnormalities in the endosomal or lysosomal systems (Supplementary Fig. 15 ).
We concluded from these studies that the presentation of β-GlcCer by CD1d is a substantial component of the TCR-mediated activation signal provided to iNKT cells by BMDCs after TLR agonist exposure. Because bacteria might contain iNKT cell lipid antigens in addition to TLR agonists, we investigated the relative functional contribution of β-GlcCer as a self lipid antigen in the activation of iNKT cells by whole bacteria. Ugcg silencing resulted in less activation of iNKT cells in response to BMDCs cultured together with Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae or Listeria monocytogenes (Fig. 8a) . As we noted after LPS exposure in BMDCs, B4galt6 silencing did not diminish iNKT cell activation. These results suggested that β-GlcCer contributes to iNKT cell activation during bacterial infection.
To extend the physiological importance of β-GlcCer accumulation in BMDCs after LPS exposure, we examined β-GlcCer concentrations in vivo during infection. As a model of Gram-negative bacterial sepsis, we transferred E. coli intravenously and assessed β-GlcCer in the spleen. At 24 h after E. coli injection, β-GlcCer increased as a portion of the total polar lipids and remained elevated at 48 h after injection (Fig. 8b) . As a model of Gram-positive bacterial infection, we investigated S. pneumoniae pulmonary infection, a model in which iNKT cells have been shown to have a prominent role 11, 36 . Because S. pneumoniae produces α-glucosyldiacylglycerol (GlcDAG), a lipid that co-migrates with β-GlcCer by TLC in some solvent systems, we modified our solvent system to separate these two lipids and included GlcDAG as a lipid standard. As we saw in the spleen after E. coli infection, we observed an increase in β-GlcCer concentrations in the total lung polar lipid extracts of mice infected with S. pneumoniae (Fig. 8c) . This increase was prominent by day 3 after infection, corresponding to iNKT cell activation in this model 11 . We concluded from these studies that β-GlcCer accumulates in involved organs after bacterial infection.
DISCUSSION
Although iNKT cells are considered to be innate lymphocytes, they use the machinery of the adaptive immune system to express TCRs of limited diversity. The nature of the specificity of these invariant TCRs, and how this specificity might regulate activation of an innate lymphocyte population, are fundamental in understanding the increasingly appreciated role of innate lymphocytes in immunity. Because iNKT cells are activated in contexts where foreign lipid antigens may not always be present to provide cognate TCR-mediated signals, self lipid antigens have been proposed to participate in this activation. Identification of the involved self lipid antigens has remained a central issue in the field 33 . We now find that β-GlcCer, the simplest GSL, acts as a physiologically relevant self lipid antigen for iNKT cells.
Here we have shown activity for both naturally occurring and synthetic β-GlcCer in vitro with mouse iNKT cell hybridomas, mouse and human primary iNKT cell lines and freshly isolated human iNKT cells. By injecting β-GlcCer intravenously, we showed activity in vivo on unperturbed mouse iNKT cells. β-GlcCer also activates in an APC-free system, as shown with plate-bound, lipid-loaded CD1d. As an additional important proof of principle, β-GlcCer-loaded CD1d tetramers specifically stain a subset of iNKT cells from both mouse and human directly ex vivo, providing strong evidence that the iNKT cell TCR can directly bind CD1d complexes loaded with β-GlcCer C 24:1 . Based on these observations, we conclude that β-GlcCer activates both mouse and human iNKT cells through a direct cognate interaction between the iNKT cell TCR and β-GlcCer-loaded CD1d.
In mammals, GSLs have diverse structures, varying in both the fatty acyl chain and the carbohydrate head group. Examination of each of these structural features for β-GlcCer provides important insight into the crucial determinants of iNKT cell self antigenicity. We found evidence that the activity of β-GlcCer varies with N-acyl chain structure. Such differences also have been observed for α-GalCer variants and have been attributed to the kinetics, stability and subcellular location of antigen loading 23, 24, 37 . Notably, β-GlcCer C 24:1 , the most potent β-GlcCer variant tested for iNKT cells, is the specific form found in the highest abundance in mammalian lymphoid tissues.
Various approaches have been used to clarify the contribution of the lipid head group in iNKT cell activation. Two informative studies looked at the role of the iNKT TCR complementary-determining region 3 β-loop (CDR3β) in iNKT cell autoreactivity. Research from one study has shown that naturally occurring, high-affinity human iNKT cell TCR interactions with CD1d are dependent on TCR CDR3β and that β-GlcCer-loaded tetramers, similar to OCH-loaded tetramers, could discriminate between high-and low-affinity iNKT cell TCRs 32 . Research from a second study examined a particularly autoreactive V α 14-V β 6 iNKT TCR generated by random mutagenesis of mouse CDR3β and showed that multiple cellular lipids can influence the binding of this TCR to CD1d, either positively or negatively 29 . Although several higher-order GSLs resulted in less binding relative to unloaded tetramer, β-GlcCer and β-GalCer did not have this effect 29 . These studies, although not specifically implicating monohexosyl ceramides as iNKT self antigens, are consistent with the idea that β-GlcCer might support iNKT cell TCR binding to CD1d for autoreactive iNKT cells.
Comparison of co-crystal structures of CD1d-β-GSL-TCR with the reported CD1d-α-GalCer-TCR structure 38 has shown that the primary β-linked sugar is 'molded' by the TCR into a configuration similar to that seen with α-GalCer, providing a structural explanation for the antigenic activity of β-linked lipids 39, 40 . In addition to iGB3, other antigenic primary β-linked GSLs have been described, including β-mannosylceramide and β-GalCer C 12:0 (refs. 26, 27, 41) . Together with our data, such reports suggest that CD1d-bound, β-linked monohexosyl ceramides can fulfill the structural requirements of a self antigen for iNKT cell TCR. The 'energetic penalty' incurred with altering the conformation of a monohexosyl ceramide bound to CD1d to adopt a topology similar to that of α-GalCer is probably lower than that required for more complex GSLs, and our data suggest that the acyl chain composition of the lipid may also have a role in this process.
In addition to fulfilling structural requirements for antigenicity, a physiologically relevant self antigen must be present at sites of iNKT cell activation. As with iGB3, β-GalCer and β-mannosylceramide would not be found in any substantial amounts at most sites of peripheral iNKT cell activation. We show that β-GlcCer C 24:1 , however, is detectable in lymphoid tissues, accumulates during infection and, therefore, is likely to have a physiological role. This is of particular importance, as elution studies have shown that CD1d presents lipids representative of the total cellular lipid profile or compartment surveyed 21, 42, 43 .
Several lines of evidence have suggested the possibility that GSLs contribute to iNKT cell self reactivity, although GSLs may not be the only lipid class contributing to iNKT cell autoreactivity 25 . Notably, an iNKT-cell-dependent immunomodulatory or inhibitory role A r t i c l e s has been reported for β-GlcCer in vivo 44 . Through the use of GSL synthesis inhibitors, published studies have indirectly indicated that GSLs are important iNKT cell antigens in BMDCs after TLR agonist stimulation 9, 10, 20 . Our identification of a specific antigenic β-GSL, β-GlcCer, allowed us to target the pathways involved in the synthesis of that lipid. Silencing of Ugcg, the gene that encoded β-GlcCer synthase, resulted in less self-reactivity and lower response of iNKT cells to BMDCs in the presence of LPS or whole bacteria. Targeting B4galt6, which encodes the main enzyme involved in the conversion of β-GlcCer to β-LacCer, increased self reactivity as well as the response of iNKT cells to LPS and some bacteria, likely as a result of the observed accumulation of β-GlcCer. Our siRNA silencing results, controlled for antigen presentation, IL-12 production, APC activation status and endosomal morphology, strongly suggest that β-GlcCer has an important role in the CD1d-dependent signal in APCs during many infections. Additionally, β-GlcCer has been reported to accumulate in spleen, serum and liver of LPS-exposed rodents 45 , suggesting that endosomal uptake of systemically circulating β-GlcCer by APCs could provide another source of antigen. Thus, the induction of GSL biosynthesis, both in antigen-presenting cells and systemically, provides a mechanism for danger sensing by iNKT cells, which is mediated by β-GlcCer.
Two signals have an important role in iNKT cell activation during microbial infection: the first is a lipid antigen presented by CD1d to the iNKT cell TCR, and the second is an inflammatory cytokine, such as IL-12. We propose that β-GlcCer, a self antigen that accumulates after APC activation, provides a major TCR signal for iNKT cells. The ability of an iNKT cell to be activated by the integration of APCdependent innate signals explains how these cells, with an invariant TCR, can be activated in multiple pathologic contexts in the absence of foreign lipid antigens. The recognition of the self antigen β-GlcCer by an invariant TCR is a clear example of the translation of an innate danger signal with the machinery of the adaptive immune system, a mechanism that may apply to other innate T lymphocytes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
